000169734 001__ 169734
000169734 005__ 20240229133654.0
000169734 0247_ $$2doi$$a10.1038/s41416-021-01471-1
000169734 0247_ $$2pmid$$apmid:34226683
000169734 0247_ $$2ISSN$$a0007-0920
000169734 0247_ $$2ISSN$$a1532-1827
000169734 0247_ $$2altmetric$$aaltmetric:108713422
000169734 037__ $$aDKFZ-2021-01539
000169734 041__ $$aEnglish
000169734 082__ $$a610
000169734 1001_ $$0P:(DE-He78)628d5ea4d1b87c9ee351782af809119d$$aMüller, Jana$$b0$$eFirst author
000169734 245__ $$aPreventive effect of sensorimotor exercise and resistance training on chemotherapy-induced peripheral neuropathy: a randomised-controlled trial.
000169734 260__ $$aEdinburgh$$bNature Publ. Group$$c2021
000169734 3367_ $$2DRIVER$$aarticle
000169734 3367_ $$2DataCite$$aOutput Types/Journal article
000169734 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1642165256_15951
000169734 3367_ $$2BibTeX$$aARTICLE
000169734 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000169734 3367_ $$00$$2EndNote$$aJournal Article
000169734 500__ $$a#EA:D120#LA:D120# / 2021 Sep;125(7):955-965
000169734 520__ $$aChemotherapy-induced peripheral neuropathy (CIPN) is a common, unpleasant and usually long-lasting side effect of neurotoxic chemotherapeutic agents. This study aimed to investigate the preventive potential of sensorimotor- (SMT) and resistance training (RT) on CIPN.Patients (N = 170) were randomised to SMT, RT or usual care (UC). Both exercise groups trained 3×/week for a total of 105 min/week during neurotoxic chemotherapy (mean length: 20 weeks). Before and 3 weeks after neurotoxic chemotherapy, CIPN signs/symptoms were assessed via Total Neuropathy Score (TNSr; primary endpoint) and EORTC QLQ-CIPN15 questionnaire. In addition, balance (centre of pressure), muscle strength (isokinetic), quality of life (QoL, EORTC QLQ-C30) and relative chemotherapy dose intensity (RDI) were investigated. The follow-up period covered 6 months after the end of chemotherapy.Intention-to-treat analyses (N = 159) revealed no differences regarding CIPN signs/symptoms. Exploratory per-protocol analyses (minimum training attendance rate 67%; N = 89) indicated that subjectively perceived sensory symptoms in the feet increased less during chemotherapy in the adherent exercisers (pooled group: SMT+RT) than in the UC group (-8.3 points (-16.1 to -0.4); P = 0.039, ES = 1.27). Furthermore, adherent exercisers received a higher RDI (96.6 ± 4.8 vs. 92.2 ± 9.4; P = 0.045), showed a better course of muscular strength (+20.8 Nm (11.2-30.4); P < 0.001, ES = 0.57) and QoL (+12.9 points (3.9-21.8); P = 0.005, ES = 0.64). During follow-up, CIPN signs/symptoms persisted in all groups.This study demonstrates that SMT and/or RT alleviate subjectively perceived sensory CIPN symptoms in the feet and other clinically relevant cancer therapy-related outcomes, if an appropriate training stimulus is achieved.NCT02871284.
000169734 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000169734 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000169734 7001_ $$aWeiler, Markus$$b1
000169734 7001_ $$aSchneeweiss, Andreas$$b2
000169734 7001_ $$aHaag, Georg Martin$$b3
000169734 7001_ $$0P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aSteindorf, Karen$$b4
000169734 7001_ $$0P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aWick, Wolfgang$$b5
000169734 7001_ $$0P:(DE-He78)60b584aeef81e4c57fd111fa63779b73$$aWiskemann, Joachim$$b6
000169734 773__ $$0PERI:(DE-600)2002452-6$$a10.1038/s41416-021-01471-1$$n7$$p955-965$$tBritish journal of cancer$$v125$$x1532-1827$$y2021
000169734 909CO $$ooai:inrepo02.dkfz.de:169734$$pVDB
000169734 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)628d5ea4d1b87c9ee351782af809119d$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000169734 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000169734 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000169734 9101_ $$0I:(DE-HGF)0$$6P:(DE-He78)60b584aeef81e4c57fd111fa63779b73$$aExternal Institute$$b6$$kExtern
000169734 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000169734 9130_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000169734 9141_ $$y2021
000169734 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRIT J CANCER : 2019$$d2021-01-28
000169734 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-28
000169734 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-28
000169734 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-01-28
000169734 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-01-28
000169734 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-01-28
000169734 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-28
000169734 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2021-01-28
000169734 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-28
000169734 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-01-28
000169734 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-01-28
000169734 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-28
000169734 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-28
000169734 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-28
000169734 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBRIT J CANCER : 2019$$d2021-01-28
000169734 9201_ $$0I:(DE-He78)D120-20160331$$kD120$$lD120 Angewandte Tumor-Immunität$$x0
000169734 9201_ $$0I:(DE-He78)C110-20160331$$kC110$$lBewegung, Präventionsforschung und Krebs$$x1
000169734 9201_ $$0I:(DE-He78)B320-20160331$$kB320$$lKKE Neuroonkologie$$x2
000169734 980__ $$ajournal
000169734 980__ $$aVDB
000169734 980__ $$aI:(DE-He78)D120-20160331
000169734 980__ $$aI:(DE-He78)C110-20160331
000169734 980__ $$aI:(DE-He78)B320-20160331
000169734 980__ $$aUNRESTRICTED